机构：[a]Medical Research Center, The Third People’s Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, The Second Chengdu Hospital Affiliated toChongqing Medical University, Chengdu, Sichuan 610031, China[b]Department of Clinical Laboratory, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610031,China四川省人民医院四川省肿瘤医院[c]Department of General Surgery, No. 42 Hospital of PLA, Leshan, Sichuan 614000, China[d]Department of Clinical Laboratory, Nanchong Central Hospital, Nanchong, Sichuan 637000, China[e]Department of Gastroenterology, The Third People’s Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, The Second Chengdu HospitalAffiliated to Chongqing Medical University, Chengdu, Sichuan 610031, China
Background: At present, the overall sensitivity and specificity of blood biomarkers are insufficient for a diagnosis of colorectal cancer (CRC). Methods: We analyzed the serum synaptophysin like 1 (sSYPL1) in controls, adenoma patients, CRC patients, pre- and postoperative CRC patients by ELISA. Results: The upregulation of SYPL1 was confirmed in CRC tissues at both mRNA and protein levels. Consistently, sSYPL1 was significantly higher in CRC patients than in either controls (t = 14.50, P < 0.0001) or adenoma patients (t = 10.56, P < 0.0001) and was associated with lymph node invasion (chi(2) = 4.27, P = 0.039). ROC curves showed that sSYPL1 performed superbly in distinguishing CRC patients from controls (AUC: 0.9481; sensitivity: 86.09%, specificity: 91.01%) and adenoma (AUC: 0.8631; sensitivity: 98.68%, specificity: 78.08%). This performance was much better than that of carcinoembryonic antigen (CEA) or carbohydrate antigen 19-9 (CA19-9). Even for patients with low CEA levels (under 5 ng/mL), SYPL1 maintained the same high performance for identification of CRC. Furthermore, sSYPL1 levels declined significantly after radical surgery (t = 5.903, P < 0.0001). Conclusion: sSYPL1 might be an outstanding marker for CRC diagnosis, especially for patients with low CEA levels.
基金：
Application and Basic Research Foundation of Science and Technology Department of Sichuan province [2017JY0094]; Foundation of Chengdu Municipal Science and Technology Bureau [2018-YF05-00227-SN]; Medical Research Project of Chengdu Municipal Health Commission [2018080]
第一作者机构：[a]Medical Research Center, The Third People’s Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong University, The Second Chengdu Hospital Affiliated toChongqing Medical University, Chengdu, Sichuan 610031, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Lei Liu,Qiao He,Yan Li,et al.Serum SYPL1 is a promising diagnostic biomarker for colorectal cancer[J].CLINICA CHIMICA ACTA.2020,509:36-42.doi:10.1016/j.cca.2020.05.048.
APA：
Lei Liu,Qiao He,Yan Li,Bing Zhang,Xiaobin Sun...&Yuanbiao Guo.(2020).Serum SYPL1 is a promising diagnostic biomarker for colorectal cancer.CLINICA CHIMICA ACTA,509,
MLA：
Lei Liu,et al."Serum SYPL1 is a promising diagnostic biomarker for colorectal cancer".CLINICA CHIMICA ACTA 509.(2020):36-42
